TABLE 2.
Multivariable Cox regression analysis of CD8+ tumor‐infiltrating lymphocytes and clinicopathological variables on overall survival and progression‐free survival
| Overall survival | Progression‐free survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p‐Value | HR | 95% CI | p‐Value | |
| CD8+ TILs | ||||||
| High density versus low density | 0.392 | 0.198–0.777 | 0.007 | 0.534 | 0.299–0.953 | 0.034 |
| IASLC histological grading | ||||||
| Grade 3 versus grade 1 + grade 2 | 4.177 | 1.811–9.633 | 0.001 | 3.380 | 1.722–6.635 | <0.001 |
| Postoperative adjuvant chemotherapy | ||||||
| Yes versus no | 1.728 | 0.866–3.449 | 0.121 | 1.671 | 0.915–3.051 | 0.095 |
| pStage | ||||||
| Stage II + III versus I | 1.313 | 0.663–2.601 | 0.435 | 1.289 | 0.712–2.335 | 0.401 |
| Grading‐Immunoscore type | ||||||
| Type B versus type A | 2.416 | 0.891–6.552 | 0.083 | 2.554 | 1.150–5.670 | 0.021 |
| Type C versus type A | 7.242 | 3.036–17.274 | <0.001 | 4.842 | 2.382–9.844 | <0.001 |
| Type B versus type C | 0.334 | 0.152–0.734 | 0.006 | 0.527 | 0.270–1.030 | 0.061 |
| pStage | ||||||
| Stage II + III versus I | 1.281 | 0.826–2.955 | 0.479 | 1.262 | 0.698–2.282 | 0.441 |
| Postoperative adjuvant chemotherapy | ||||||
| Yes versus no | 1.745 | 0.871–3.493 | 0.116 | 1.665 | 0.911–3.044 | 0.098 |
Abbreviations: CI, confidence interval; HR, hazard ratio; IASLC, International Association for the Study of Lung Cancer; OS, overall survival; PFS, progression‐free survival; TIL, tumor‐infiltrating lymphocyte.